Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2833–2856 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: Migraine
Interventions: Galcanezumab, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 986 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 49
States / cities: Phoenix, Arizona • Apple Valley, California • Los Angeles, California + 44 more

Conditions: Cystic Fibrosis
Interventions: LAU-7b, Placebo oral capsule; Drug
Lead sponsor: Laurent Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 27
States / cities: Long Beach, California • Los Angeles, California • Sacramento, California + 24 more

Conditions: Infections
Interventions: Endotoxin, Lipopolysaccharide, LPS, Endotoxin, Lipopolysaccharide, LPS /Epinephrine, Placebo, Hydrocortisone; Biological
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 40 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer
Interventions: Ascorbic Acid, Docetaxel, Laboratory Biomarker Analysis, Pharmacological Study, Placebo, Quality-of-Life Assessment; Dietary Supplement · Drug · Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Annapolis, Maryland • Baltimore, Maryland + 3 more

Conditions: Infertility
Interventions: Bravelle(follicle stimulating hormone), Saline ( placebo); Drug · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Female only
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Healthy Volunteers
Interventions: TAK-418, TAK-418 Matching Placebo; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 2
States / cities: Glendale, California • Salt Lake City, Utah

Conditions: Healthy Volunteers
Interventions: MAS825, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Tempe, Arizona • Overland Park, Kansas

Conditions: Giant Cell Arteritis
Interventions: Sarilumab SAR153191, Sarilumab matching placebo, Prednisone, Prednisone matching placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 50 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 6
States / cities: Boca Raton, Florida • Gainesville, Florida • Iowa City, Iowa + 3 more

Conditions: Neuropathic Pain, Mechanical Hypersensitivity
Interventions: AZD2066, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 38
States / cities: Tucson, Arizona • Los Angeles, California • Sacramento, California + 35 more

Conditions: Rheumatoid Arthritis, Musculoskeletal and Connective Tissue Diseases
Interventions: Adalimumab, Placebo; Biological · Other
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 13
States / cities: Tuscaloosa, Alabama • Thousand Oaks, California • Jacksonville, Florida + 10 more

Conditions: Rhinitis, Allergic, Perennial, Hay Fever
Interventions: Ciclesonide nasal, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 2 Years to 5 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Pain
Interventions: transcranial direct current stimulation (tDCS), Lidocaine cream, Capsaicin cream, Control cream; Device · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 21 Years to 50 Years
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Obesity
Interventions: NNC0487-0111, Placebo (matched to NNC0487-0111); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 606 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 13
States / cities: Anniston, Alabama • Walnut Creek, California • Orlando, Florida + 9 more

Conditions: Cystitis, Interstitial
Interventions: ERB-041; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 13
States / cities: Glendora, California • Redding, California • San Diego, California + 8 more

Conditions: Healthy
Interventions: ExPEC4V, Placebo; Biological
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Wichita, Kansas • Knoxville, Tennessee

Conditions: Nausea and Vomiting, Chemotherapy-Induced
Interventions: ondansetron, moxifloxacin, saline; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Osteogenesis Imperfecta (OI)
Interventions: AGA2115, Placebo; Drug · Other
Lead sponsor: Angitia Incorporated Limited; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 9
States / cities: Phoenix, Arizona • New Haven, Connecticut • Wilmington, Delaware + 6 more

Conditions: Carcinoma, Non-Small-Cell Lung, Non-small Cell Lung Cancer, NSCLC
Interventions: Erlotinib (tarceva), Placebo; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 65
States / cities: Birmingham, Alabama • Huntsville, Alabama • Fort Smith, Arkansas + 57 more

Conditions: COVID19
Interventions: RTB101, Placebo; Drug
Lead sponsor: Restorbio Inc.; Industry
Eligibility: 65 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Middletown, Rhode Island

Conditions: Arthritis, Rheumatoid
Interventions: Placebo, Sirukumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 878 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 81
States / cities: Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 78 more

Conditions: Schizophrenia
Interventions: D-cycloserine, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Uveitis, Posterior, Uveitis, Intermediate, Uveitis
Interventions: Brepocitinib PO QD, Placebo PO QD; Drug
Lead sponsor: Priovant Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 371 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 53
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 44 more

Conditions: Marijuana Dependence
Interventions: eszopiclone, Placebo, ramelteon, zolpidem; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: PreDiabetes
Interventions: Low-dose bitter melon, High-dose bitter melon, Placebo; Dietary Supplement
Lead sponsor: Midwest Center for Metabolic and Cardiovascular Research; Other
Eligibility: 18 Years to 74 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 3
States / cities: Miami Gardens, Florida • Port Saint Lucie, Florida • Addison, Illinois

Search by objective public record fields.

Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study

Study of LAU-7b in the Treatment of Cystic Fibrosis in Adults

The Effects of Hydrocortisone in Endotoxemia in Normal Volunteers

Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer

Concomitant Administration of FSH With HCG Improves Oocyte Maturation and Quality Double -Blinded Randomized Trial

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Multiple Oral Dose of TAK-418 in Healthy Female Participants

A First-in-human Study to Investigate the Safety, Tolerability and Pharmacokinetics of MAS825 in Healthy Volunteers

Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA

AZD2066 Neuropathic Pain - Mechanical Hypersensitivity

A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects

To Assess the Safety of Ciclesonide, Applied as a Nasal Spray at Three Dose Levels, in the Treatment of Perennial Allergic Rhinitis in Pediatrics (BY9010/M1-405)

Neuromodulation of Lidocaine and Capsaicin Cream Effects on Pain Experience

AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss

Study Evaluating Orally Administered ERB-041 in Subjects With Active Interstitial Cystitis

A Study to Evaluate Safety and Immunogenicity of the ExPEC4V Clinical Trial Material After a Single Intramuscular Dose and a Second Dose 6 Months Later in Healthy Participants Aged 18 Years and Older

To Investigate the Effect of Intravenous Ondansetron on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects

Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)

Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes

A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)

Once Weekly D-cycloserine for Schizophrenia

A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis

The Effect of Marijuana and Prescription Medications in Mood, Performance and Sleep

Effects of Bitter Melon on Cardiometabolic Health